NIH began clinical trial evaluating second COVID-19 booster shots in adults
On Mar. 31, 2022, the National Institutes of Health (NIH) and Moderna announced a phase 2 clinical trial…
-
-
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the U.S. Food and Drug Administration (FDA) had given clearance to…
-
Moderna received FDA approval for EUA of 2nd booster dose of its COVID-19 vaccine, mRNA-1273
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
-
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
-
US Food and Drug Administration revised EUA for sotrovimab due to Omicron BA.2 subvariant
On Mar. 25, 2022, GlaxoSmithKline and Vir Biotechnology announced that the US Food and Drug Administration (FDA) had…
-
Moderna finalized strategic partnership with Australian government
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
-
Quest Diagnostics granted CDC contract to support COVID-19 infection and vaccination seroprevalence research
On Mar. 23, 2022, Quest Diagnostics announced that it had been granted a contract by the Centers for…
-
Pfizer supplied UNICEF 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-Income countries
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
-
Windtree announced results from phase 2 study of lucinactant for COVID-19 associated ARDS and Lung Injury
On Mar. 22, 2022, Windtree Therapeutics announced results from its Phase 2 study of lucinactant (KL4 surfactant) for…
-
Moderna announced new supply agreement for 2023 with Switzerland for seven million doses of COVID-19 booster vaccine
On Mar. 21, 2022, Moderna announced announced a supply agreement with the Swiss Federal Government for seven million…
-
Twist Bioscience launched synthetic RNA positive controls for SARS-CoV-2 encapsulated in imagene’s stainless steel capsules
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
-
Health Canada authorized Moderna’s COVID-19 vaccine in children (6-11 Years)
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
-
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax™ (heat stable COVID-19…
-
Moderna submited amendment to EUA for an additional booster dose of its COVID-19 vaccine in the U.S.
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
-
Moderna to supply Japan with additional 70 million doses of COVID-19 booster vaccine
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
-
Roche provided molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern
On Mar. 15, 2022, Roche announced available testing solutions that can identify the SARS-CoV-2 B.1.1.529 variant and differentiate…
-
CDC reported effectiveness of 2-Dose BNT162b2 mRNA vaccine in preventing SARS-CoV-2 infection among children
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by the Centers for Disease Control and…
-
Oragenics engages KBI Biopharma to support development of intranasal COVID-19 vaccine candidate NT-CoV2-1
On Mar. 10, 2022, Oragenics announced that it had entered into an agreement with KBI Biopharma for the…
-
Mandatory masking in schools reduced COVID-19 cases during Delta surge
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
-
City of Hope COVID-19 vaccine showed effectiveness in phase 1 trial
On Mar. 10, 2022, a COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to…
-
Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease…
-
University of Oxford reported brain regions related to smell show decline following mild COVID-19
On Mar. 7, 2022, researchers from the University of Oxford have used data from UK Biobank participants to…
-
Possible case of deer-to-human SARS-CoV-2 transmission
On Mar. 3, 2022, a study carried out in southwestern Ontario identified a highly mutated variant of SARS-CoV-2…
-
Sorrento announced COVISHIELD antibody nasal drops prevent productive SARS-CoV-2 infections
On Mar. 2, 2022, Sorrento Therapeutics announced that new preclinical results demonstrated that pretreating an animal with intranasal…
-
Possible case of deer-to-human SARS-CoV-2 transmission
On Feb. 25, 2022, researchers announced that wildlife reservoirs of SARS-CoV-2 can lead to viral adaptation and spillback…
-
University of Oxford researchers created largest ever human family tree
On Feb. 24, 2022, researchers from the University of Oxford have used data from UK Biobank participants to…
-
Medicago and GSK announced approval by Health Canada of COVIFENZ, an adjuvanted plant-based COVID-19 vaccine
On Feb. 24, 2022, Medicago and GlaxoSmithKline announced that Health Canada had granted approval for COVIFENZ, COVID-19 vaccine,…
-
Biotechnology | COVID-19 | Infectious Disease | NIH | Vaccine | WHO
Novavax and Serum Institute of India announced first EUA of COVID-19 vaccine in adolescents =12 to <18 in India
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
-
Health Canada authorized Novavax COVID-19 vaccine
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
-
Therapeutic Goods Administration of Australia authorized Moderna’s Covid-19 vaccine in children (6-11 Years)
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
